Advocacy in rare disease: Driving technology advances – 2023 Webinar
Explore how patient advocacy drives rare disease innovation, improves diagnosis, and accelerates technology-driven ad...
Volv Global provides data-driven understanding of disease endpoints and outcomes to support pricing and reimbursement calculations, regulatory and HTA submissions, payer evidence packages and comparative economics studies with real-world evidence.Â
Analyse real-world treatment pathways and their effectiveness to define more precise endpoints for better analysis of disease progression and outcomes.
Compare treatment effectiveness via analysis of real-world outcomes of different intervention.
Identify cohorts more precisely and at an early stage for better longitudinal assessment of patient health outcomes.
Understand the real-world impact on quality of life and healthcare utilisation for payer evidence packages and comparative economic studies
Value, access and HEOR in the face of complexity
Integrating real-world evidence (RWE) to understand the real-world clinical, economic, and social impact of disease on quality of life and healthcare utilisation.
Disparate healthcare systems and patient populations create inconsistent datasets lacking standardised outcome measures.
Linking medical records to cost-related data is often difficult.
Differences in healthcare access across regions affect generalisability of findings.
Supporting Clinical Development
We find undiagnosed and misdiagnosed patients, expanding the pool of patients for clinical trial recruitment.
We find patients before the development of traditional symptoms, before they are given conventional therapies.
We enable triage of patients according to prognosis of outcomes, e.g., fast progressors, or progressors to more acute symptoms.
We differentiate and cluster heterogeneous patient cohorts for more accurate definition of trial inclusion and exclusion criteria.
Leading AI/ML methodology to support Value and Access, HEOR
Through comprehensive data integration from clinical and claims sources, inTrigue equips Value & Access and HEOR teams to quantify the real-world performance of therapies. By merging clinical, claims, and other healthcare data, inTrigue provides a holistic view of disease burden, allowing for robust cost-effectiveness and outcomes analyses. This data-backed insight aids stakeholders in demonstrating value to payers, supporting earlier detection strategies, and ultimately enhancing patient access through clearer evidence of a therapy’s impact.Â
Shaping the future today
Explore how patient advocacy drives rare disease innovation, improves diagnosis, and accelerates technology-driven ad...
Reflecting on Rare Disease Day: Awareness is an Act of Love – Guest Article by Jessica Lynn of Rareatives
The diagnostic gap: stopping cancer patients from losing a winnable battle means treating earlier diagnosis as a stra...
The podcast Uncovering the uncommon: Advances in Rare Disease diagnosis explores diagnostic delays and how to shorte...
Volv Global will be exhibiting at Faces of Industrial Research (FIR) 2026 on Friday, February 20th, 2026, at the EPFL...
The podcast Uncovering the uncommon: Advances in Rare Disease diagnosis explores diagnostic delays and how to shorte...
Chronic Obstructive Pulmonary Disease remains under-recognised & under-diagnosed. How do we ensure COPD patients ...
At Rare Patient Voice, we've learned one crucial truth over the past decade:Â data can reveal patterns, but only patie...
Volv Global at Digital Lounge @Davos 2026: CEO Christopher Rudolf speaks on applied AI, cost-efficient healthcare and...
MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification. Novel therapies only achieve the...
Bridging gaps across the CLL care pathway, Part 2: Knowing When To Treat – AI for Transformation, Infection Risk, and...
Bridging gaps across the CLL care pathway, Part 1: From Signal to Stratification – Reimagining Early CLL Care through...